Trials / Completed
CompletedNCT04092452
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06650833 | 400 mg QD |
| DRUG | PF-06700841 | 45 mg QD |
| DRUG | PF-06826647 | 400 mg QD |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2019-12-02
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
- First posted
- 2019-09-17
- Last updated
- 2023-06-15
- Results posted
- 2023-06-15
Locations
77 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04092452. Inclusion in this directory is not an endorsement.